Masimo Shareholders Approve Danaher Merger Agreement Terms

An announcement from Masimo ( (MASI) ) is now available.

On May 1, 2026, Masimo shareholders approved the company’s merger agreement with Danaher Corporation at a virtual special meeting, with roughly 70.68% of outstanding shares represented and an overwhelming majority voting in favor. Investors also backed, on an advisory basis, the merger-related executive compensation, clearing key corporate governance hurdles for the transaction.

Under the agreed terms, each Masimo share will be converted into the right to receive $180 in cash when Danaher’s Mobius Merger Sub is combined with Masimo, leaving Masimo as an independent operating company within Danaher’s Diagnostics segment. The deal, expected to close in 2026 subject to regulatory approvals and customary conditions, is positioned by management as delivering compelling value to shareholders while bolstering Masimo’s global growth prospects in patient monitoring and diagnostics.

The most recent analyst rating on (MASI) stock is a Hold with a $180.00 price target. To see the full list of analyst forecasts on Masimo stock, see the MASI Stock Forecast page.

Spark’s Take on MASI Stock

According to Spark, TipRanks’ AI Analyst, MASI is a Neutral.

The score is driven primarily by mixed financial performance (strong and improving cash flow and better gross margins, but continued losses and a recent revenue decline). Technicals are supportive with a clear uptrend, while valuation is constrained by a negative P/E and no dividend data. Corporate events add support from the announced $180/share Danaher deal, partially offset by litigation-related execution risk.

To see Spark’s full report on MASI stock, click here.

More about Masimo

Masimo Corporation is a global medical technology company specializing in patient monitoring solutions, including advanced noninvasive measurements, sensors, patient monitors, and automation and connectivity platforms. Its flagship Masimo SET® pulse oximetry technology is widely used in hospitals worldwide and is the primary pulse oximetry system at all 10 top U.S. hospitals in Newsweek’s 2025 World’s Best Hospitals ranking.

The company focuses on improving patient outcomes, reducing the cost of care, and expanding noninvasive monitoring to new sites and clinical applications across the healthcare sector. Masimo’s technologies are deployed on an estimated 200 million patients annually, underscoring its entrenched position in the global diagnostics and monitoring market.

Average Trading Volume: 1,666,352

Technical Sentiment Signal: Buy

Current Market Cap: $9.35B

See more data about MASI stock on TipRanks’ Stock Analysis page.